Results 191 to 200 of about 2,359,169 (353)

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

AI-Driven Advances in Parkinson's Disease Neurosurgery: Enhancing Patient Selection, Trial Efficiency, and Therapeutic Outcomes. [PDF]

Brain Sci
Valerio JE, Aguirre Vera GJ, Fernandez Gomez MP, Zumaeta J, Alvarez-Pinzon AM.   +4 more
europepmc   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Scoping review of indications for robotic ventral mesh rectopexy: addressing variability in patient selection. [PDF]

Int J Colorectal Dis
Grossi U, Ascanelli S, de'Angelis N, Sinatti E, D'Ovidio A, Schena CA, Gallo G, Mollica E, Lauria A, Frasson A, Vittadello F, Naldini G.   +11 more
europepmc   +1 more source

Multidisciplinary experience in the selection of patients for tubal sterilization [PDF]

, 1995
Ricardo Barini, Aarão Mendes Pinto-Neto, Lúcia Helena Simões Costa, Arlete de Souza Barros, Nádia Maria Marchi, Lúcia de Lourdes Ferreira, Ermelinda Maria Bueno, Akemi Murayama, Cláudia Sampaio do Nascimento, Laise Potério dos Santos Hinz, Olivia Josane Barreto de Almeida   +10 more
openalex   +1 more source

The selection of patients for thyroidectomy

Journal of British Surgery, 1965
openaire   +3 more sources

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Histotripsy of Liver Tumors: Patient Selection, Ethical Discussions, and How We Do It. [PDF]

Cancers (Basel)
Uysal M, Wehrle CJ, Satish S, Knott E, Hong H, Allkushi E, Schlegel A, Berber E, Aucejo F, Kim J, Kwon DCH.   +10 more
europepmc   +1 more source

Magnetic resonance angiography is an accurate imaging adjunct to duplex ultrasound scan in patient selection for carotid endarterectomy [PDF]

, 2000
Martin R. Back, Jeffrey S. Wilson, Greg Rushing, N Stordahl, Craig Linden, Brad Johnson, Dennis F. Bandyk   +6 more
openalex   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source